Phathom Pharmaceuticals News

Buy Rating Justified by Strong Market Acceptance of Phathom Pharmaceuticals' V Oquezna

TipRanksApr 26 08:25 ET

SynOx Therapeutics Announces $75m Series B Round to Fund Phase 3 Trial of Potential Best-in-class Treatment for TGCT

SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a $75m...

PR NewswireApr 22 03:30 ET

13D Filings -- Barron's

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen

Barron'sApr 19 21:30 ET

MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors -- Barrons.com

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen

Barron'sApr 19 15:03 ET

12 Most Shorted Stocks in 2024

Yahoo FinanceApr 19 11:02 ET

Buy Rating Affirmed for Phathom Pharmaceuticals Amid Strong Uptake of V Oquezna

TipRanksApr 19 09:25 ET

Analysts Offer Insights on Healthcare Companies: Rallybio (RLYB), Phathom Pharmaceuticals (PHAT) and Amylyx Pharmaceuticals Inc (AMLX)

TipRanksApr 11 06:30 ET

It's worth buying! Needham: In the wave of mergers and acquisitions in the pharmaceutical industry, these three US stocks are most likely to be acquired

Phathom Pharma, Rhythm, and Vaxcyte are most likely to be targeted by pharmaceutical companies.

Zhitong FinanceApr 8 02:23 ET

Phathom Pharma, Rhythm, Vaxcyte Most Likely Takeover Targets in Pharma - Analyst

Seeking AlphaApr 7 08:00 ET

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors -- Barrons.com

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen

Barron'sApr 5 18:30 ET

Optimistic Outlook for Phathom Pharmaceuticals' Voquezna Despite Prescription Data Fluctuations

TipRanksApr 5 09:35 ET

Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Phathom Pharmaceuticals (PHAT)

TipRanksApr 1 06:50 ET

ANGI, MLKN and KOD Are Among After Hour Movers

Seeking AlphaMar 27 16:50 ET

Phathom Pharmaceuticals(PHAT.US) Officer Sells US$153.51K in Common Stocks

$Phathom Pharmaceuticals(PHAT.US)$ Officer Curran Terrie sold 16,851 shares of Common Stocks on Mar 22, 2024 at an average price of $9.11 for a total value of $153.51K.Source: Announcement What is sta

moomoo NewsMar 26 16:49 ET

Express News | Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

Moomoo 24/7Mar 22 14:14 ET

Positive Prescription Trends and Resilience Prompt Buy Rating for Phathom Pharmaceuticals

TipRanksMar 22 09:35 ET

Phathom Pharmaceuticals Is Maintained at Buy by Needham

Phathom Pharmaceuticals Is Maintained at Buy by Needham

Dow JonesMar 15 10:45 ET

Express News | Needham Maintains Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

Moomoo 24/7Mar 15 10:34 ET

Analysts' Top Healthcare Picks: Longboard Pharmaceuticals (LBPH), Phathom Pharmaceuticals (PHAT)

TipRanksMar 15 10:30 ET

Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by Needham

Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by Needham

Dow JonesMar 8 14:32 ET